Press Releases

In This Section

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 8, 2017
MYALEPT® Total Net Revenues Increase 28% Over Prior Quarter, Excluding One-Time AdjustmentsGlobal Expansion Plans for Metreleptin Opportunity UnderwayCompany Updates Guidance for FY 2017 Total Net RevenuesConference call to be held today at 8:30 a.m. ET VANCOUVER, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a...
Aug 2, 2017
VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark DiPaolo to its board of directors, effective immediately. Jason Aryeh, chairman o...
Jul 28, 2017
VANCOUVER, British Columbia, July 28, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Tuesday, August 8, 2017 at 8:30 a.m. Eastern ...
Jun 26, 2017
VANCOUVER, British Columbia, June 26, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that it has been added to the Russell 3000® and Russell Microcap® as part of the FTSE's annual recon...
Jun 12, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., June 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data by researchers at the American Diabetes Association Scientific S...
Jun 1, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of John J. Orloff, M.D. to its board of directors, effective as of July 1...
May 9, 2017
Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer  Defined Clinical Development Plan for Zuretinol Following Positive FDA MeetingCompany Reiterates FY 2017 Total Net Revenues Guidance Between $155 and $165 millionConference call to be held today at 8:30 a.m. ET VANCOUVER, British Columbia, May 09, 2017 (GLOBE NEWSWI...
May 5, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data by academic researchers at the American Association of...
May 3, 2017
VANCOUVER, British Columbia, May 03, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. Eastern Time...
Apr 25, 2017
VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Bloom Burton & Co. Healthcare Investor Conference in Tor...
Apr 19, 2017
VANCOUVER, British Columbia, April 19, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that, as part of its cost rationalization process, the Company's request to voluntarily delist it...
Apr 4, 2017
VANCOUVER, British Columbia & CAMBRIDGE, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of four separate data presentations by academic researchers in...
Mar 31, 2017
VANCOUVER, British Columbia, March 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan, M.D. to its board of directors, effective immediately. Dr. Corri...
Mar 31, 2017
VANCOUVER, British Columbia, March 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced its observance of World Lipodystrophy Day. Chief Executive Officer Mary Szela said, "We sup...
Mar 30, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, and its subsidiary today announced the presentation of data by academic researchers at ENDO 2...

= add release to Briefcase